Mirvetuximab soravtansine Selected FRα/test/prior-regimen conditions are source-linked. | selected_indicated_therapy FDA indication exists; only selected conditions checked. | mirv, mirv-label |
Pembrolizumab + paclitaxel ± bevacizumab Selected PD-L1/test/prior-regimen conditions are source-linked. | selected_indicated_therapy FDA combination indication exists; optional bevacizumab requires separate review. | pembro, pembro-label, paclitaxel-label, bev-label |
Relacorilant + nab-paclitaxel Selected prior-regimen and prior-bevacizumab conditions are source-linked. | selected_indicated_therapy FDA combination indication exists; full safety assessment remains required. | rela, rela-label, nab-paclitaxel-label |
Paclitaxel (single agent) Conventional recurrent-disease discussion candidate. | conventional_therapy Ovarian indication exists; the contemplated schedule requires review. | nci, paclitaxel-label |
Pegylated liposomal doxorubicin (single agent) Conventional recurrent-disease discussion candidate. | conventional_therapy Ovarian post-platinum indication exists; complete applicability remains unassessed. | nci, pld-label |
Topotecan (single agent) Conventional recurrent-disease discussion candidate. | conventional_therapy HYCAMTIN ovarian indication exists; verify current product and schedule labeling. | nci, topotecan-label |
Gemcitabine (single agent; off-label here) NCI discusses single-agent use in platinum-resistant recurrence. | conventional_therapy Off-label in this setting as monotherapy; the labeled ovarian combination concerns platinum-sensitive relapse. | nci, gemcitabine-label |
Bevacizumab + paclitaxel Named bevacizumab partner with a separate prior-chemotherapy count. | selected_indicated_therapy FDA combination indication exists; selected conditions and safety inventory only. | bev-label, nci, paclitaxel-label |
Bevacizumab + pegylated liposomal doxorubicin Named bevacizumab partner with a separate prior-chemotherapy count. | selected_indicated_therapy FDA combination indication exists; selected conditions and safety inventory only. | bev-label, nci, pld-label |
Bevacizumab + topotecan Named bevacizumab partner with a separate prior-chemotherapy count. | selected_indicated_therapy FDA combination indication exists; selected conditions and safety inventory only. | bev-label, nci, topotecan-label |
Pembrolizumab alone (MSI-H or dMMR solid tumours) Gated only on what KEYTRUDA §1.8 states and the record holds: MSI-H or dMMR result, an FDA-authorized test, and progression after earlier treatment. Route: a subcutaneous form, KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa), is approved for the same MSI-H or dMMR solid-tumour use; it has its own dose and route and is not interchangeable with intravenous pembrolizumab. | selected_indicated_therapy FDA label indication (KEYTRUDA §1.8). The §1.8 paragraph carries no accelerated-approval statement in SPL version 229. | pembro-msi-label |
Dostarlimab alone (dMMR solid tumours) Current JEMPERLI §1.3/§2.1 plus the therapy-specific FDA companion-diagnostic intended use: reviewed VENTANA dMMR or MI Cancer Seek MSI-H. An unverified or different assay calls for report/intended-use review; it is not automatically a clinical exclusion or an instruction to repeat IHC. | selected_indicated_therapy FDA accelerated approval, JEMPERLI §1.3; no satisfactory alternative remains a clinician judgement. §2.1 selection and the named FDA PMA intended uses are checked separately from historical GARNET evidence. | jemperli-label-v15-selection, ventana-p210001-jemperli, mi-cancer-seek-p240010-jemperli, dostarlimab-label |
Trastuzumab deruxtecan alone (HER2 IHC 3+ solid tumours) Gated only on what ENHERTU §1.6 states and the record holds: HER2 IHC 3+ and earlier systemic treatment. The label names no scoring criteria for this use and says no FDA-authorized test for it is available, so neither is a gate. | selected_indicated_therapy FDA accelerated approval (ENHERTU §1.6), based on objective response rate and duration of response; continued approval may depend on a confirmatory trial. | tdxd-label |
Clinical-trial review Trial consideration is part of review in this setting. | care_pathway Not a named-trial match, enrollment determination or trial availability claim. | nci |
Supportive and palliative care review Concurrent symptom relief and goals-of-care review. | care_pathway A care review pathway, not a medication or hospice-eligibility decision. | palliative |
Carboplatin + paclitaxel (platinum-sensitive recurrence; ICON4 / GOG-0213) Improved 2-year survival (57% vs 50%) and median OS (29 vs 24 months) vs conventional platinum therapy in ICON4. | conventional_therapy FDA platinum/taxane palliative recurrent ovarian indications; randomized survival advantage over non-taxane platinum in ICON4. | carboplatin, paclitaxel, pm_12826431, pdq_ovarian |
Carboplatin + paclitaxel + bevacizumab -> bevacizumab maintenance (GOG-0213) Improved median PFS (13.8 vs 10.4 months, HR 0.61) and ORR (78% vs 56%) over carboplatin + paclitaxel in GOG-0213. | selected_indicated_therapy FDA-approved in combination with carboplatin and paclitaxel followed by single-agent Avastin for platinum-sensitive recurrent ovarian cancer (AVASTIN §1.9). | avastin, carboplatin, paclitaxel, pm_28438473, pdq_ovarian |
Carboplatin + gemcitabine (platinum-sensitive recurrence >=6m; Study 1) Improved median PFS (8.6 vs 5.8 months, HR 0.72) and ORR (47.2% vs 30.9%) over single-agent carboplatin in Study 1. | selected_indicated_therapy FDA-approved gemcitabine in combination with carboplatin for advanced ovarian cancer relapsed at least 6 months after completion of platinum-based therapy (gemcitabine §1.1). | gemcitabine, carboplatin, pdq_ovarian |
Carboplatin + gemcitabine + bevacizumab -> bevacizumab maintenance (OCEANS / AVF4095g) Improved median PFS (12.4 vs 8.4 months, HR 0.46-0.484) and ORR (78.5% vs 57.4%) in OCEANS; no OS improvement. | selected_indicated_therapy FDA-approved in combination with carboplatin and gemcitabine followed by single-agent Avastin for platinum-sensitive recurrent ovarian cancer (AVASTIN §1.9; OCEANS enrolled no prior recurrent chemo and no prior bevacizumab). | avastin, gemcitabine, carboplatin, pm_22529265, pdq_ovarian |
Carboplatin + pegylated liposomal doxorubicin (CALYPSO) Longer median PFS vs carboplatin + paclitaxel (11.3 vs 9.4 months, HR 0.823) with lower alopecia/neuropathy and similar OS in CALYPSO (NCI PDQ). | conventional_therapy Prospective phase 3 noninferiority/superiority PFS trial CALYPSO summarized in NCI PDQ ovarian treatment summary; neuropathy-sparing platinum doublet. | doxil, carboplatin, pdq_ovarian |
BRCA-mutated PARP inhibitor maintenance after response to platinum (SOLO-2 / NOVA / ARIEL3) Substantial PFS prolongation in BRCA-mutated platinum-sensitive recurrent maintenance (SOLO-2 19.1 vs 5.5m; NOVA gBRCAmut 21.0 vs 5.5m; ARIEL3 tBRCA 16.6 vs 5.4m). | selected_indicated_therapy FDA-approved maintenance for recurrent ovarian cancer in CR/PR to platinum: olaparib (LYNPARZA §1.2, germline or somatic BRCA), niraparib (ZEJULA §1.2, deleterious/suspected deleterious germline BRCA ONLY), rucaparib (RUBRACA §1.2, deleterious BRCA germline or somatic). | lynparza, zejula, rubraca |
Secondary cytoreductive surgery evaluation before platinum therapy (DESKTOP III) Longer median OS with cytoreductive surgery + platinum chemotherapy vs chemotherapy alone (53.7 vs 46.0 months, HR 0.75) when selected by positive AGO score (75.5% macroscopic complete resection). | care_pathway Prospective randomized phase 3 trial DESKTOP III (NCT01166737; PMID 34874631) in first platinum-sensitive relapse (>=6 months) with positive AGO score (ECOG 0, complete resection at 1L surgery, ascites <500 mL). | pm_34874631, pdq_ovarian |